Longevity Biotech, Inc. – Trademark Portfolio
Entity Type: 03
Longevity Biotech, Inc. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include HYBRIDTIDE and LONGEVITY BIOTECH. The owner is based in Philadelphia, PA.
600 S. 43rd Street
Philadelphia, PA 19104
Showing of trademarks Trademarks
Trademark Classifications
Longevity Biotech, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Longevity Biotech, Inc. have?
Longevity Biotech, Inc. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Longevity Biotech, Inc. file in?
Longevity Biotech, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Longevity Biotech, Inc.'s most well-known trademarks?
Longevity Biotech, Inc.'s registered trademark portfolio includes well-known marks such as HYBRIDTIDE and LONGEVITY BIOTECH. These are among 2 currently registered trademarks in the portfolio.
What is Longevity Biotech, Inc.'s trademark registration success rate?
Longevity Biotech, Inc. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.